ReGen Biologics Inc. (RGBOQ) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Instruments & Supplies 산업에서 운영. 본사 소재지는 Hackensack, NJ, 미국. 현재 CEO는 William G. Rodkey D.V.M..
RGBOQ 을(를) 보유 IPO 날짜 1996-06-28, 15 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $97.00.
ReGen Biologics Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company's proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics Inc. was formerly known as Aros Corp and changed its name to ReGen Biologics Inc. in November, 2002. ReGen Biologics Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey. On April 8, 2011, ReGen Biologics Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2011.
